To contentTo navigationTo search
Logotype

Investors

Press releases

Press releases

2021

Implantica included in Nasdaq First North 25 index

04.01.2021
 | Other press releases
Implantica AG (publ) today announced it is joining the FN 25 index from the start of trading this morning.

Implantica inkluderas i Nasdaq First North 25-index

04.01.2021
 | Other press releases
Implantica AG (publ) meddelade idag att de inkluderas i NASDAQs FN 25-index från handelns start idag.

2020

Implantica publishes Interim Report Q3, January-September 2020

18.11.2020
 | Inside information
“It is with great pleasure that we provide our first quarterly report since listing on Sweden’s Nasdaq First North Premier Growth Market on 21 September.”

- Peter Forsell, CEO and Founder of Implantica AG

Implantica publiserar Interimrapporten Q3, Januari-September 2020

18.11.2020
 | Inside information
“Det är med stor glädje som vi presenterar vår första kvartalsrapport sedan noteringen på Sveriges Nasdaq First North Premier Growth Market den 21 september.”

- Peter Forsell, VD för och grundare av Implantica

Implantica presenterar tredje kvartalet för 2020 den 18 November kl. 10:30

12.11.2020
 | Other press releases
Implantica bjuder in investerare till en presentation av delårsrapporten för tredje kvartalet 2020 den 18 november klockan 10:30. Delårsrapporten för tredje kvartalet kommer att publiceras klockan 08:00 CET samma morgon.

Implantica presents the third quarter 2020 on November 18, at 10:30 CET

12.11.2020
 | Other press releases
Implantica invites investors to a presentation of the third quarter 2020 at 10:30 a.m. CET on November 18. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.

Implanticas kliniska prövning av RefluxStop™ visar exceptionella treårsresultat

11.11.2020
 | Other press releases
Implantica AG (publ) meddelade idag de treåriga uppföljningsresultaten för bolagets medicinska implantat RefluxStop™. Efter tre år var resultaten anmärkningsvärda; ingen av studiens 47 patienter behövde dagligen äta protonpumpshämmare (PPI), vilket alla gjorde före operationen.

Implantica’s RefluxStop™ trial shows exceptional three-year follow-up result

11.11.2020
 | Other press releases
Implantica AG (publ) today announced the three-year follow-up results of their medical implant RefluxStop™. After three years, results were remarkable; none of the 47 patients in the study were in need of regular daily use of PPIs (proton-pump inhibitors), which were taken by all before surgery.

Implantica files pre-submission with FDA for RefluxStop™

02.11.2020
 | Other press releases
Implantica AG (publ) today announced it has completed a pre-submission to the U.S. Food and Drug Administration (FDA) for RefluxStop™, a CE-marked medical implant for the prevention of gastroesophageal reflux disease (GERD).

Implantica lämnar pre-submission till FDA för RefluxStop™

02.11.2020
 | Other press releases
Implantica AG (publ) meddelade idag att bolaget har lämnat in en så kallad pre-submission till amerikanska läkemedelsverket Food and Drug Administration (FDA) för RefluxStop™, ett CE-märkt medicinskt implantat för att förebygga sura uppstötningar i matstrupen så kallad gastroesofageal reflux disease (GERD).
Load more

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here